Palbociclib
Brand name: Ibrance
Rank #23 of 500 drugs by total cost
$755.1M
Total Cost
48,329
Total Claims
$755.1M
Total Cost
1,812
Prescribers
$16K
Cost per Claim
692
Beneficiaries
48,469
30-Day Fills
$417K
Avg Cost/Provider
27
Avg Claims/Provider
About Palbociclib
Palbociclib (sold as Ibrance) was prescribed 48,329 times by 1,812 Medicare Part D providers in 2023, costing the program $755.1M. At $16K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 20 | Paliperidone Palmitate (Invega Sustenna) | $832.3M | 252,388 |
| 21 | Insulin Aspart (Novolog Flexpen) | $831.6M | 958,823 |
| 22 | Budesonide/Formoterol Fumarate (Symbicort) | $759.4M | 1,452,561 |
| 23 | Palbociclib (Ibrance) | $755.1M | 48,329 |
| 24 | Nintedanib Esylate (Ofev) | $703.7M | 53,928 |
| 25 | Ruxolitinib Phosphate (Jakafi) | $698.1M | 46,655 |
| 26 | Cyclosporine (Restasis) | $684.1M | 723,620 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology